Geron GERN Proceeds from sale of future royalties
Proceeds from sale of future royalties at other companies
Other financials
Where this comes from
Reported directly by Geron in its filing.
Tagged under the XBRL concept gern:ProceedsFromSaleOfFutureRoyalties.
The official record: Geron’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Geron's proceeds from sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Geron's proceeds from sale of future royalties?
- Geron (GERN) reported proceeds from sale of future royalties of $0 in Q4 2025.
- How has Geron's proceeds from sale of future royalties changed year-over-year?
- Geron's proceeds from sale of future royalties decreased by 100.0% year-over-year, from $31.25M to $0.
- What does proceeds from sale of future royalties mean?
- This metric measures the upfront cash received by a company in exchange for granting a third party the rights to a portion of future revenue streams, such as royalties or milestone payments from drug sales. It is a strategic financing tool used by biopharmaceutical firms to secure non-dilutive capital for R&D without issuing new equity. While it provides immediate liquidity, it represents a trade-off against future potential revenue and long-term profitability.